M&A / Property
TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia
Pioneering passive thermal protection for temperature-sensitive injectables amid aggressive global distribution expansion.
Executive Summary
- TempraMed Technologies signed a non-binding Letter of Intent (LOI) with Rawafed Health International Company to establish a 5-year exclusive distribution agreement for its temperature-sensitive medication storage products in Saudi Arabia.
- The proposed arrangement includes minimum purchase commitments of approximately US$3.1 million over the 5-year term.
- Exclusivity is contingent upon successful regulatory approval from the Saudi Food and Drug Authority (SFDA) and the placement of a first commercial order of at least US$170,000.
- The partnership targets Saudi Arabia's rapidly growing diabetes and GLP-1 therapy market, leveraging Rawafed's local regulatory and commercialization capabilities to launch the VIVI Cap and future solutions.
- The LOI is non-binding, with no guarantee of a definitive agreement or execution on contemplated terms.
Material Impact
- The Saudi Arabia LOI represents an incremental step in TempraMed's ongoing global distribution expansion, following similar agreements in Brazil, Turkey, Benelux, Israel, and Panama over the past six months.
- The financial commitment is modest, averaging ~$620,000 annually over five years, which is small relative to the company's current cash position and operating burn rate.
- As a non-binding LOI contingent on regulatory approval and an initial order, it carries no immediate revenue recognition or cash flow impact.
- The announcement does not alter the company's fundamental liquidity profile or address the going concern warning issued in the Q1 2026 financials.
VIVI · Price
Company Overview
- TempraMed Technologies Ltd. develops and commercializes battery-free, passive thermal-insulation devices designed to protect temperature-sensitive medications (insulin, GLP-1s, biologics, epinephrine) from heat and temperature excursions.
- The product portfolio includes VIVI Cap, VIVI Cap Smart, VIVI Epi, VIVI Med, and the upcoming VIVI Box platform.
- The company is executing a strategic pivot from direct-to-consumer online sales to a B2B distribution model, partnering with pharmacy chains, HMOs, and regional distributors across North America, Europe, the Middle East, and Latin America.
- The company holds multiple international patents and has secured FDA registration for its core devices, while pursuing reimbursement validation through independent ROI models.
More from TempraMed Technologies Ltd.
Jun 30, 2026 · 03:06